TITLE

Abnormal Hepatic Biochemistries in Patients With Inflammatory Bowel Disease

AUTHOR(S)
Mendes, Flavia D.; Levy, Cynthia; Enders, Felicity B.; Loftus Jr., Edward V.; Angulo, Paul; Lindor, Keith D.
PUB. DATE
February 2007
SOURCE
American Journal of Gastroenterology;Feb2007, Vol. 102 Issue 2, p344
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES: The relationship between abnormal hepatic biochemistries and inflammatory bowel disease (IBD) is unclear. We determined the prevalence of abnormal hepatic biochemistries and chronic liver disease in a cohort of IBD patients, and we compared patients with normal and abnormal liver biochemistries. METHODS: Patients with IBD evaluated at our institution between January 1, 2000 and December 31, 2000 were identified. Data on gender, age, IBD subtype, extent and activity, medications, liver disease history, liver biochemistries, and vital status were collected. The χ2 test, Student's t-test, and Cox proportional regression were used. RESULTS: We identified 544 patients with available hepatic biochemistries. Abnormal hepatic biochemistries were found in 159 (29%). Defined chronic liver disease was present in 5.8% of patients (primary sclerosing cholangitis in 4.6%). The prevalence of abnormal hepatic biochemistries was 27% for those with active IBD and 36% for those in remission ( P= 0.06). Patients with abnormal hepatic biochemistries were less frequently on 5-aminosalicylates (35% vs 51%, P < 0.001), and a smaller proportion was alive at last follow-up (90.4% vs 98.5%, P < 0.0001). The age-adjusted risk of death was 4.8 times higher in patients with abnormal hepatic biochemistries, after excluding patients with any diagnosis of liver disease. CONCLUSIONS: Abnormal hepatic biochemistries were present in nearly one-third of our patients, and surprisingly, they were not associated with IBD activity. Abnormal hepatic biochemistries and chronic liver disease appeared to have a negative impact on vital status. Persistently abnormal hepatic biochemistries should be evaluated, and not attributed to IBD activity.
ACCESSION #
23774285

 

Related Articles

  • The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease. Qazi, Taha; Shah, Bhavesh; El-Dib, Mohammed; Farraye, Francis; Farraye, Francis A // Digestive Diseases & Sciences;Feb2016, Vol. 61 Issue 2, p589 

    Objective: Few studies have assessed the loss of efficacy or patient and caregiver satisfaction with rapid infliximab infusions. The aim of this study is to assess the tolerability, loss of efficacy and to describe the impact on resource utilization and patient satisfaction in rapid...

  • Early Nodular Hyperplasia of the Liver Occurring With Inflammatory Bowel Diseases in Association With Thioguanine Therapy. Shastri, Sunita; Dubinsky, Marla C.; Poordad, F. Fred; Vasiliauskas, Eric A.; Geller, Stephen A. // Archives of Pathology & Laboratory Medicine;Jan2004, Vol. 128 Issue 1, p49 

    Context.--Nodular hyperplasia (also referred to as nodular regenerative hyperplasia and nodular regenerative hyperplasia of the liver) is a sequel to therapy with thioguanine in patients with hematologic malignancies. Recently, 6-thioguanine has been used to treat patients with inflammatory...

  • The Routine Use of Fecal Calprotectin in Clinical Pediatric Practice: Almost there or Still Issues to Address? Bourdillon, Gabrielle; Biskou, Olga; MacKinder, Mary; Khan, Muhammad Jaffar; Tsiountsioura, Melina; Clark, Clare; Russell, Richard K; McGrogan, Paraic; Edwards, Christine Ann; Gerasimidis, Konstantinos // American Journal of Gastroenterology;Nov2013, Vol. 108 Issue 11, p1811 

    A letter to the editor is presented in response to the article "The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: A systematic review and meta-analysis" by P. Henderson, N.H. Anderson and D.C. Wilson in 2013 issue.

  • Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy. Jiang, Weiwei; Li, Xuhang // Molecular Diagnosis & Therapy;Jun2015, Vol. 19 Issue 3, p141 

    Biomarkers of inflammatory bowel disease (IBD) are non-invasive or minimally invasive tests for IBD diagnosis and/or prognosis as well as assessment of disease activity and response to therapy. Here, we update the current status of IBD biomarkers, including serological, fecal, and genetic (DNA...

  • Effective Treatment Strategies for Inflammatory Bowel Disease. Rosh, Joel R. // Journal of Managed Care Medicine;2013, Vol. 16 Issue 2, p16 

    No abstract available.

  • The Immunological Basis of Inflammatory Bowel Disease. Silva, Francesca A. R.; Rodrigues, Bruno L.; Ayrizono, Maria de Lourdes S.; Leal, Raquel F. // Gastroenterology Research & Practice;12/14/2016, p1 

    Inflammatory bowel diseases (IBDs) are chronic ailments, Crohn’s disease and ulcerative colitis being the most important. These diseases present an inflammatory profile and they differ according to pathophysiology, the affected area in the gastrointestinal tract, and the depth of the...

  • Inflammatory Bowel Disease in Older People. Grimpen, Florian; Pavli, Paul // Journal of Pharmacy Practice & Research;2008, Vol. 38 Issue 3, p234 

    Inflammatory bowel disease (IBD) can affect patients of all ages. The majority of patients are diagnosed in the second or third decade of life, but a minority develop the disease at an advanced age. Diagnosis can be delayed due to the preconception that IBD mainly affects young people, and the...

  • Inflammatory bowel disease. Robinson, Andrew // GP: General Practitioner;3/6/2009, p33 

    The article offers information on the causes, diagnosis and management of inflammatory bowel diseases (IBD). Researchers relate that IBD results from the interaction of gut organisms and the immune system of genetically susceptible patients. It states that IBD is a particular problem for...

  • Successful Azathioprine Treatment with Metabolite Monitoring in a Pediatric Inflammatory Bowel Disease Patient Homozygous for TPMT*3C. Mi-Na Lee; Hye In Woo; Yoo Min Lee; Ben Kang; Jong-Won Kim; Yon Ho Choe; Soo-Youn Lee // Yonsei Medical Journal;Nov2013, Vol. 54 Issue 6, p1545 

    Thiopurine S-methyltransferase (TPMT) methylates purine analogues, showing TPMT activity in inverse relation to concentrations of active metabolites such as 6-thioguanine nucleotide (6-TGN). With conventional dosing of thiopurines, patients with homozygous variant TPMT alleles consistently...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics